Re:Cognition Health featured in “Hope in the Age of Dementia” exploring the latest ground-breaking developments to overcome the condition.

Alzheimer’s Disease International (ADI), the global voice on Dementia and ITN Productions Industry News have launched a news-style programme “Hope In The Age of Dementia” featuring Re:Cognition Health and biopharmaceutical company TauRx. The poignant programme showcases the latest developments in care, research and technology, with a special focus on advancing and accelerating solutions for Alzheimer’s disease globally.


“Hope In The Age of Dementia” features volunteers who are participating in clinical trials at Re:Cognition Health, testing new generation medication designed to slow down or stop the progression of Alzheimer’s disease. Trial participants and their study partners are interviewed about their experiences in undertaking clinical trials and how this has positively impacted their lives.

Over 50 million people are affected by dementia worldwide and this number is expected to more than triple by 2050 placing an unprecedented strain on health systems globally. The programme hears from leaders in the field of neuroscience and neurodegeneration, research, drug discovery, care and support, explaining the importance of new treatment pathways, early diagnostic tools, clinical trials, risk reduction, timely diagnosis and health and care innovation.

Dr Emer MacSweeney, CEO and Consultant Neuroradiologist, who is interviewed on the programme comments, “We are absolutely delighted to be included in such an important programme, working with biopharmaceutical company TauRx, to help educate and innovate the field of dementia research. We are so proud to provide study volunteers the opportunity to gain early access new generation treatments designed to slow down or stop the progression of Alzheimer’s disease and other neurological conditions, helping to change the future for generations to come.”

Professor Claude Wischik, CEO of TauRx says, “It was a pleasure to be part of this news-style program showcasing the latest developments in care, research and technology. The impact of dementia globally has been brought to focus once again by the devastating effects of the Covid-19 pandemic, and now, more than ever, the pharmaceutical industry needs to re-focus its efforts in finding new and effective ways to combat this disease. Our focus at TauRx has always been in the field of neurodegenerative disease and we hope that our contribution to this program will help highlight the progress of research and the importance of patients taking part in clinical trials.”


The Re:Cognition Health Clinics in London, Surrey, Birmingham, Plymouth and Washington DC are major centres for international trials of disease-modifying and new symptomatic drugs for Alzheimer’s disease and other neurological conditions. The multi-disciplinary team work collaboratively to provide a full service, patient-centred approach using the latest progressive medical research and evidence-based treatments. Further information on the clinical trials can be found by clicking here


“Hope in the Age of Dementia” can be viewed by clicking here


Back To All News